BACKGROUND/AIMS: The aim of the present, open-labeled, randomized study was to determine the efficacy and safety of different doses of consensus interferon plus ribavirin in the initial treatment of chronic hepatitis C. METHODS: One hundred and one genotype 2/3 patients were randomized to receive 9 mcg (group A, n=48) or 18 mcg (group B, n=53) of consensus interferon thrice weekly plus ribavirin (1000/1200 mg/daily) for 24 weeks and 92 genotype 1 patients to receive 9 mcg (group C, n=47) or 18 mcg (group D, n=45) of consensus interferon plus ribavirin for 48 weeks. RESULTS: In an intention-to-treat analysis, the sustained virologic response at 24-week follow-up was 69% and 66% for group A and B (P=0.77) and 40% and 36% for group C and D (P=...
BACKGROUND: Clinical trials have shown that the combination of pegylated interferon/ribavirin induce...
AIM: To compare the efficacy and safety of recombinant human IFN beta-1a alone or in combination w...
Objective: To evaluate the efficacy and tolerability of two different daily doses of interferon-\u3b...
Background/Aims: The aim of the present, open-labeled, randomized study was to determine the efficac...
Background/Aims: The aim of the present, open-labeled, randomized study was to determine the efficac...
AIM: To assess the efficacy of different schedules of consensus interferon (CIFN) plus ribavirin in ...
AIM: To assess the efficacy of different schedules of consensus interferon (CIFN) plus ribavirin in ...
BACKGROUND: Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more ...
OBJECTIVE: The treatment of patients with hepatitis C virus (HCV) genotype 1 infection remains disap...
Objective: To evaluate the efficacy and tolerability of two different daily doses of interferon-α (l...
Background & Aims: The aim of this study was to compare interferon (IFN)- ribavirin combination ther...
Background: Efficacy and safety of interferon induction therapy alone or in combination with ribavir...
Background: Efficacy and safety of interferon induction therapy alone or in combination with ribavir...
BACKGROUND: Data on the efficacy of Peg-interferon/ribavirin therapy for chronic hepatitis C are mos...
Background: Efficacy and safety of interferon induction therapy alone or in combination with ribavir...
BACKGROUND: Clinical trials have shown that the combination of pegylated interferon/ribavirin induce...
AIM: To compare the efficacy and safety of recombinant human IFN beta-1a alone or in combination w...
Objective: To evaluate the efficacy and tolerability of two different daily doses of interferon-\u3b...
Background/Aims: The aim of the present, open-labeled, randomized study was to determine the efficac...
Background/Aims: The aim of the present, open-labeled, randomized study was to determine the efficac...
AIM: To assess the efficacy of different schedules of consensus interferon (CIFN) plus ribavirin in ...
AIM: To assess the efficacy of different schedules of consensus interferon (CIFN) plus ribavirin in ...
BACKGROUND: Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more ...
OBJECTIVE: The treatment of patients with hepatitis C virus (HCV) genotype 1 infection remains disap...
Objective: To evaluate the efficacy and tolerability of two different daily doses of interferon-α (l...
Background & Aims: The aim of this study was to compare interferon (IFN)- ribavirin combination ther...
Background: Efficacy and safety of interferon induction therapy alone or in combination with ribavir...
Background: Efficacy and safety of interferon induction therapy alone or in combination with ribavir...
BACKGROUND: Data on the efficacy of Peg-interferon/ribavirin therapy for chronic hepatitis C are mos...
Background: Efficacy and safety of interferon induction therapy alone or in combination with ribavir...
BACKGROUND: Clinical trials have shown that the combination of pegylated interferon/ribavirin induce...
AIM: To compare the efficacy and safety of recombinant human IFN beta-1a alone or in combination w...
Objective: To evaluate the efficacy and tolerability of two different daily doses of interferon-\u3b...